Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Enli LiuDavid MarinPinaki BanerjeeHomer A MacapinlacPhilip ThompsonRafet BasarLucila Nassif KerbauyBethany OvermanPeter ThallMecit KaplanVandana NandivadaIndresh KaurAna Nunez CortesKai CaoMay DaherChitra HosingEvan N CohenPartow KebriaeiRohtesh MehtaSattva NeelapuYago NietoMichael L WangWilliam WierdaMichael KeatingRichard ChamplinElizabeth J ShpallKatayoun RezvaniPublished in: The New England journal of medicine (2020)
Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects. (Funded by the M.D. Anderson Cancer Center CLL and Lymphoma Moonshot and the National Institutes of Health; ClinicalTrials.gov number, NCT03056339.).
Keyphrases
- nk cells
- natural killer cells
- diffuse large b cell lymphoma
- papillary thyroid
- healthcare
- public health
- acute lymphoblastic leukemia
- mental health
- acute myeloid leukemia
- quality improvement
- squamous cell
- hodgkin lymphoma
- health information
- childhood cancer
- climate change
- risk assessment
- lymph node metastasis
- replacement therapy